Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
68 results about "Transcriptional Regulatory Elements" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The transcription region consists of exons and introns. The regulatory elements include promoter, response element, enhancer and silencer (not shown). Downstream refers to the direction of transcription and upstream is opposite to the transcription direction.
Transcriptional regulatory elements of biological pathways tools, and methods
InactiveUS20090018031A1Determine effectNucleotide librariesLibrary screeningHuman DNA sequencingRegulation of gene expression
The present invention provides compositions, kits, assemblies, libraries, arrays, and high throughput methods for large scale structural and functional characterization of gene expression regulatory elements in a genome of an organism, especially in a human genome, that are part of a common pathway. In one aspect of the invention, an array of expression constructs is provided, each of the expression constructs comprising: a nucleic acid segment operably linked with a reporter sequence in an expression vector such that expression of the reporter sequence is under the transcriptional control of the nucleic acid segment. The present invention can have a wide variety of applications such as in personalized medicine, pharmacogenomics, and correlation of polymorphisms with phenotypic traits.
Owner:SWITCHGEAR GENOMICS
Methods and compositions relating to improved lentiviral vector production systems
ActiveUS7629153B2Increasing its biosafetySafe transfection and transductionVectorsGenetic material ingredientsTranscriptional Regulatory ElementsTransgene
The present invention provides HIV-derived lentivectors which are multiply modified to create highly safe, efficient, and potent vectors for expressing transgenes for gene therapy. The lentiviral vectors comprise various combinations of an inactive central polypurine tract, a stuffer sequence, which may encode drug susceptibility genes, and a mutated hairpin in the 5′ leader sequence that substantially abolishes replication. These elements are provided in conjunction with other features of lentiviral vectors, such as a self-inactivating configuration for biosafety and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments for inherited and acquired disorders, gene-therapies for cancers and other disease, the creation of industrial and experimental production systems utilizing transformed cells, as well as for the study of basic cellular and genetic processes.
Owner:RES DEVMENT FOUND
Methods and compositions relating to improved lentiviral vector production systems
ActiveUS8900858B2Increasing its biosafetySafe transfection and transductionVectorsGenetic material ingredientsDiseaseTranscriptional Regulatory Elements
Owner:RES DEVMENT FOUND
Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
ActiveUS7662795B2Peptide/protein ingredientsGenetic material ingredientsTranscriptional Regulatory ElementsCytotoxicity
The present invention relates to compositions and methods for enhancing the oncolytic activity of replication-competent, target cell-specific adenovirus vectors by modification of the E1A gene product. The target cell-specific replication-competent adenovirus vectors comprise a chimera of an adenovirus gene essential for replication, preferably an early gene, and the Androgen receptor (or a portion thereof) under the transcriptional control of a cell type-specific transcriptional regulatory element (TRE). By providing for cell type-specific transcription through the use of one or more cell type-specific TREs, the adenovirus vectors effect prostate-specific cytotoxicity due to selective replication.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and / or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.
Owner:CG ONCOLOGY INC
Inducing Premature Senescence to Stabilize Stem Cell Feeder Layer Cells
InactiveUS20090142839A1Unlimited proliferative capacitySupport growthGenetically modified cellsArtificial cell constructsAnkyrin bindingConditional expression
The present invention provides stem cell feeder layer cell lines that contain are readily triggered to differentiation. The expression vector encodes the senescence-triggering factors (STFs) consisting of Cip / Kip, INK4A, Cy protein or ankyrin-binding protein motifs. Each expression vector also contains an inducible transcription regulation element for conditional expression of the STFs.
Owner:SHILOH LAB
Universal markers of transgenesis
InactiveUS20030154502A1Genetic engineeringFermentationHeterologousTranscriptional Regulatory Elements
The invention relates to methods, cells and nucleic acids for making transgenic animals. The methods generally comprise introducing into a genome of an animal a genetic construct comprising a transcriptional regulatory element operably linked to a heterologous marker gene encoding a marker, wherein the element drives expression of the marker across genera transgenic in the construct sufficient to visually detect the marker in photoreceptive cells or organs, and selecting for transgenesis by visually detecting the marker in a photoreceptive cell or organ of the animal.
Owner:WIMMER ERNST A +2
Methods and compositions relating to improved lentiviral vector production systems
ActiveUS20100062524A1Increasing its biosafetySafe transfection and transductionVectorsGenetic material ingredientsTranscriptional Regulatory ElementsTransgene
The present invention provides HIV-derived lentivectors which are multiply modified to create highly safe, efficient, and potent vectors for expressing transgenes for gene therapy. The lentiviral vectors comprise various combinations of an inactive central polypurine tract, a stuffer sequence, which may encode drug susceptibility genes, and a mutated hairpin in the 5′ leader sequence that substantially abolishes replication. These elements are provided in conjunction with other features of lentiviral vectors, such as a self-inactivating configuration for biosaftey and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments for inherited and acquired disorders, gene-therapies for cancers and other disease, the creation of industrial and experimental production systems utilizing transformed cells, as well as for the study of basic cellular and genetic processes.
Owner:RES DEVMENT FOUND
Transcriptional control element of human lung carcinoma cell NGAL gene promoter region
InactiveCN1974768AFermentationVector-based foreign material introductionRegulation of gene expressionTranscriptional Regulatory Elements
The present invention relates to gene expression controlling technology, and discloses one kind of transcriptional control element of human lung carcinoma cell NGAL gene promoter region. The present invention identifies human lung carcinoma cell NGAL gene promoter region for the first time, inserts the promoter sequence with gradually deleting 5' end sequence and partial modified controlling element to the upstream of the report gene to constitute serial eukaryotic expression plasmids, transfects mammal cell for instantaneous expression, and determines the key control element of human NGAL gene promoter in lung carcinoma cell transcription activity. The present invention is significant in the research of NGAL in the tumor cell expression control mechanism and NGAL targeting clinical treatment.
Owner:SHANTOU UNIV MEDICAL COLLEGE
IL-12 expression carrier as well as eukaryotic cell strain expressed thereby and uses thereof
ActiveCN101200730APeptide/protein ingredientsFermentationTranscriptional Regulatory ElementsCell strain
The present invention relates to a novel method of using mammalian cell efficient expression to recombine human interleukin 12 (rhIL-12). The present invention transcripts two p35 subunits and one p40 subunit of rhIL-12 to be constructed inside a same carrier; each subunit is processed for expression level regulation by a transcription regulating element, and the efficient expression of rhIL-12 is realized by introducing the regulating elements of Intron and SV40Enhancer which can improve the expression level.
Owner:广州市茵良强生物科技有限公司
Methods and compositions relating to improved lentiviral vectors and their applications
InactiveUS20100041141A1High expressionPermit transductionFactor VIIOrganic active ingredientsTranscriptional Regulatory ElementsTransgene
Owner:RES DEVMENT FOUND
Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
InactiveUS20070270580A1Increase transcriptionReplicate more efficientlySugar derivativesMicrobiological testing/measurementNucleotideTranscriptional Regulatory Elements
Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.
Owner:THE SCRIPPS RES INST
Cell lines for use in increasing protein yield from a cell culture
InactiveUS20060051861A1Increasing heterologous protein productionGenetically modified cellsReceptors for hormonesAnkyrin binding3D cell culture
The present invention provides cell lines useful in the production proteins and peptides. The cell lines contain recombinant expression constructs. The recombinant expression construct encodes the STPs consisting of the Cy protein motif and / or an ankyrin-binding protein motif. Each recombinant expression construct also contains an inducible transcription regulation element having for conditional expression of the senescence-triggering factors (STPs).
Owner:CLONEX DEV
Chimeric transcriptional regulatory element compositions and methods for increasing prostate-targeted gene expression
InactiveUS7267978B1High expressionPromoting transcriptionVectorsGenetic material ingredientsHeterologousDisease
Disclosed are compositions and methods for achieving successful treatment of disorders of the human prostate. In preferred embodiments, methods and compositions are provided that improve the specificity and safety of gene delivery vectors, and improve the prostate-specificity and activity of genetic constructs targeted for prostate-specific expression. Also disclosed are methods utilizing a variety of therapeutic genes, including those encoding tumor-specific therapeutics, e.g., TRAIL, tumor suppressors, cytotoxins, and the like, for the treatment of proliferative disorders of the prostate, and in particular, prostatic hyperplasia, prostate cancer and prostatic tumors. In preferred embodiments genetic constructs are disclosed comprising one or more prostate-specific chimeric enhancer elements in combination with one or more wildtype core enhancer elements and a prostate-specific proximal promoter that increase expression of selected heterologous genes operably positioned under their control.
Owner:RGT UNIV OF CALIFORNIA
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and / or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.
Owner:CG ONCOLOGY INC
Pathogen- or elicitor-inducible transcription regulatory element from the tobacco 5-EPI-aristolochene synthase gene and plants transformed therewith
A tobacco epi-5-aristolochene synthase transcriptional regulatory element functional in plants, plant tissue and in plant cells for pathogen inducible gene expression and a method for increasing the transcriptional expression of downstream genetic information in plants, plant tissue and plant cells are disclosed.
Owner:UNIV OF KENTUCKY RES FOUND
Sequence for expressing targeted double-recombinant apoptosis proteins of liver cancer and application thereof
InactiveCN101812448AInduce apoptosisTargeted and efficient anti-tumor effectGenetic material ingredientsDigestive systemNucleotideTranscriptional Regulatory Elements
The invention provides a sequence for expressing targeted double-recombinant apoptosis proteins of liver cancer, which is a DNA sequence for regulating the expression of two apoptosis proteins of Caspase 3 and Granzyme B by using a specific AFP promoter, and has a nucleotide sequence shown as SEQID No:1. The sequence utilizes the function of targeted regulation of an AFP enhancer / promoter transcriptional regulatory element to lead foreign gene to be expressed in liver cancer cells with positive AFP, thus realizing targeted and high-efficiency anti-tumor effect; and the sequence constructs recombinant activated type Caspase-3 molecule, applies the recombinant activated type Caspase-3 to pro-apoptotic effect for target cells, introduces granzyme B, fuses the granzyme B and the recombinant activated type Caspase-3 molecule, and mediates the apoptosis of the target cells. The invention also provides an application in preparing targeted gene drugs for treating the liver caner with the positive AFP.
Owner:ZHEJIANG UNIV
Hybrid regulatory elements
PendingCN111902539AVectorsGenetic material ingredientsTranscriptional Regulatory ElementsExpression gene
The present invention relates to hybrid transcription regulatory elements to drive gene expression, in particular hybrid promoters, designed by the fusion of at least two transcription regulatory elements with different tissue selectivity, such as two promoters driving expression in different tissues in a tissue-selective manner.
Owner:GENETHON +4
Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
ActiveUS9730996B2Improve barrier propertiesEnhance immune stimulationViral antigen ingredientsGenetic material ingredientsGene deliveryImmunodeficiency virus
The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
Owner:TEXAS BIOMEDICAL RES INST
Method for the construction of specific promoters
ActiveUS20130324440A1Increase transcriptionGood choiceSugar derivativesMicroorganismsMethod selectionTissue specific
The present application relates to a system for designing promoters for selective expression of genes. Thereby identified transcription regulatory elements are selected according to a specific methodology and used to create a library of transcription regulatory elements, which are then used to construct specific promoters, especially tissue-specific promoters.
Owner:ASKLEPIOS BIOPHARMACEUTICAL INC
Expression vector suitable for expression of a coding sequence for gene therapy
ActiveUS8309698B2Improve the level ofSugar derivativesFermentationLiver tissueTranscriptional Regulatory Elements
Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
Owner:MOGAM BIOTECH RES INST
Expression vector suitable for expressing coded sequence used for gene therapy
The invention provides an expression vector for a gene therapy, which contains a new combination of transcriptional regulatory elements. The expression vector for the gene therapy comprises a promoter, an enhancer, an untranslated region (UTR), and a locus control region (LCR). The expression vector is capable of continuously expressing in liver tissue-specific genes, thus the expression vector can be effectively used for treating thrombosis, hemophilia, liver cancer, and the like.
Owner:MOGAM BIOTECH RES INST
Expression vector suitable for expression of a coding sequence for gene therapy
ActiveUS20120282687A1Improve the level ofSugar derivativesFermentationLiver tissueTranscriptional Regulatory Elements
Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
Owner:MOGAM BIOTECH RES INST
Optimized porcine circovivus type 2 recombinant adenovirus construction method
InactiveCN106399262AIncrease target gene expressionImprove stabilityVectorsVirus peptidesShuttle vectorAutoimmune responses
The invention relates to an optimized porcine circovivus type 2 recombinant adenovirus construction method. The construction of recombinant adenovirus is completed by cloning Human cytomegalovirus first intron (Intron A) and woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) into an adenovirus shuttle vector. The construction method provided by the invention has the advantages that a Cap expression quantity is improved, so that adenovirus usage dose and adenovirus protein autoimmune response can be relieved and the preparation efficiency of the porcine circovivus type 2 recombinant adenovirus can be improved.
Owner:NORTHWEST A & F UNIV
Rapid construction method and application of ACE2 humanized mouse model
ActiveCN113684227ANucleic acid vectorOxidoreductasesInverted Repeat SequencesTranscriptional Regulatory Elements
The invention provides a transgenic vector, a method for rapidly constructing an ACE2 humanized animal model by using the transgenic vector, and application of the ACE2 humanized animal model by aiming at research and development of SARS-CoV-2 drugs. The transgenic vector comprises a PiggyBac transposon 5'end inverted repeat sequence (ITR), a CAG promoter, a human ACE2 coding region, a ribosome access site (IRES), firefly luciferase, a dial rat hepatitis post-transcriptional regulatory element (WPR), a polyA site and a 3 'end inverted repeat sequence (ITR), the transgenic vector can efficiently insert human ACE2 and luciferase gene expression cassettes into a mouse genome, and the luciferase and human ACE2 expressed transgenic mice can be rapidly screened through a luciferase living body imaging system.
Owner:SHANGHAI BIOMODEL ORGANISM SCI & TECH DEV +2
Expression vector suitable for expressing coded sequence used for gene therapy
ActiveCN102628041AVector-based foreign material introductionDNA/RNA fragmentationThrombusTranscriptional Regulatory Elements
Provided is an expression vector for gene therapy. The expression vector comprises a new combination which contains a transcriptional control element and comprises a promoter, an enhancer, an intron, an untranslated region (UTR) and a loca control region (LCP). The expression vector can continuously express specific genes of hepatic tissue so that the expression vector can be effectively used in treating thrombus forming, hemophilia, liver cancer and the like.
Owner:MOGAM BIOTECH RES INST
Expression vector suitable for expressing coded sequence for gene therapy
The invention provides an expression vector for gene therapy. The expression vector contains new combination of transcription regulation elements, and comprises a promoter, an enhancer, an intron, a UTR (untranslated region) and an LCR (locus control region). The expression vector can express specific genes of liver tissue continually, thus being applicable to treatment on thrombosis, hemophilia,liver cancer and the like effectively.
Owner:MOGAM BIOTECH RES INST
Closed IL6R CAR-T transgenic vector for relieving CRS as well as construction method and application of CAR-T transgenic vector
ActiveCN108148863AGood sealingAvoid the problem of low efficiency of in vivo deliveryVirusesPeptide/protein ingredientsSequence signalSingle-Chain Antibodies
The invention discloses a closed IL6R CAR-T transgenic vector for relieving CRS. The vector consists of an amicillin resistance gene AmpR sequence (SEQ ID NO.1), a prokaryotic replicon pUC Ori sequence (SEQ ID NO.2), a virus replicon SV40 Ori sequence (SEQ ID NO.3), an eWPRE-enhanced marmot hepatitis B virus post-transcriptional regulatory element (SEQ ID NO.11), a human EF1[alpha] promoter (SEQ ID NO.12), a lentivirus packaging cis element applied to lentivirus packaging, a human IL6R humanized single-chain antibody IL6RscFv1 (SEQ ID NO.21) or IL6RscFv2 (SEQ ID NO.22) or IL6RscFv3 (SEQ ID NO.23), an IRES ribosome bonding sequence (SEQ ID NO.25), an IL6 signal peptide (SEQ ID NO.26), a humanized antibody Fc segment (SEQ ID NO.27) and a chimeric antigen receptor for constituting a second-generation or third-generation CAR integrating recognition, transferring and promoting. In addition, the invention also discloses a construction method of the vector and an application of the vector inpreparing medicines for relieving CRS.
Owner:SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
System for producing synthetic promoters
ActiveUS7063947B2Improve efficiencyGood curative effectVectorsMicrobiological testing/measurementTranscription regulatorTranscriptional Regulatory Elements
The present application discloses a method for making and selecting a transcription enhancing combined promoter cassette, which includes constructing a library of randomly combined transcription regulatory elements, which comprise double stranded DNA sequence elements that are recognized by transcription regulators; inserting the combined transcription regulatory elements upstream of a minimum promoter followed by a reporter gene in a vector; inserting the vector into a host cell; and then screening for the cells showing enhanced expression of the reporter gene, and identifying the combined promoter cassette in the cell.
Owner:PROMOGEN
T7-RNA polymerase mutant and application thereof
ActiveCN112831484ASuitable for synthesisMicrobiological testing/measurementTransferasesCell freeArginine
The invention discloses a T7-RNA polymerase mutant. The mutant is obtained by replacing serine at the 43rd site from the N end of an amino acid sequence of wild T7-RNA polymerase with A-type amino acid or B-type amino acid, wherein the A amino acid is tyrosine, phenylalanine, leucine, lysine or aspartic acid, and the B amino acid is tryptophan, isoleucine, arginine, asparagine, glutamine, glutamic acid or proline. The T7-RNA polymerase mutant is suitable for synthesis of RNA internally containing a termination signal and RNA with a hairpin structure formed at the tail end. The method can be widely applied to the aspects of in-vitro transcription, RNA synthesis, gene editing, RNA drug synthesis, in-vivo protein expression or cell-free protein expression in-vitro translation systems, transcription terminator research, RNA-dependent RNA polymerase activity research, biological transcription regulation element synthesis and the like.
Owner:HUAZHONG UNIV OF SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com